A carregar...
Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease
BACKGROUND/AIMS: The current treatment for anemia associated with chronic kidney disease (CKD) includes the administration of erythropoiesis stimulating agents (ESAs) combined with iron supplementation. Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, has potential to treat anemi...
Na minha lista:
| Publicado no: | Nephron Clin Pract |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
S. Karger AG
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6979436/ https://ncbi.nlm.nih.gov/pubmed/31387097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000502012 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|